Literature DB >> 27981386

[Non-viral sexually transmitted infections - Epidemiology, clinical manifestations, diagnostics and therapy : Part 1: Gonococci].

P Nenoff1, A Manos2, I Ehrhard3, C Krüger4, U Paasch5, P Helmbold6, W Handrick7.   

Abstract

Approximately 1 million people are infected per day worldwide by one or more sexually transmitted infections (STI) as estimated by the World Health Organization (WHO). Gonorrhoea represents an almost exclusively sexually transmitted infection, which predominantly affects mucous membranes of the genitourinary tract. Extragenital localization of infections is also possible, e. g. in the anorectal region. Currently, only syphilis and human immunodeficiency virus (HIV) are notifiable diseases according to the Infection Protection Act in Germany. In Saxony, an extended registration ordinance according to the German Infection Protection Act is in force, which means that besides syphilis the laboratory detection of Neisseria gonorrhoeae, Chlamydia trachomatis and genital mycoplasms are also notifiable infections. In particular, beginning in 2009 in Saxony a spectacular increase of registered infections due to N. gonorrhoeae was observed and in 2015 altogether 824 infections due to N. gonorrhoeae were reported. Alarming is the increase in resistance of N. gonorrhoeae against penicillin, doxycycline, ciprofloxacin and recently also against azithromycin and third generation cephalosporins. The so-called superbug of N. gonorrhoeae, which originated in Japan with multidrug resistance against most of the currently available oral antibiotics, has now arrived in Europe. Intramuscular or intravenous injection of ceftriaxone plus oral azithromycin, each given as single dose is the standard therapy for gonorrhoea.

Entities:  

Keywords:  Azithromycin; Cefixime; Ceftriaxone; Neisseria gonorrhoeae; Resistance

Mesh:

Substances:

Year:  2017        PMID: 27981386     DOI: 10.1007/s00105-016-3905-0

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  21 in total

1.  CDC update on gonorrhea: expand treatment to limit resistance.

Authors:  Doug Campos-Outcalt
Journal:  J Fam Pract       Date:  2011-12       Impact factor: 0.493

2.  Evaluation of the new AmpliSens multiplex real-time PCR assay for simultaneous detection of Neisseria gonorrhoeae, Chlamydia trachomatis, Mycoplasma genitalium, and Trichomonas vaginalis.

Authors:  Tatiana Rumyantseva; Daniel Golparian; Christian S Nilsson; Emma Johansson; My Falk; Hans Fredlund; Alje Van Dam; Alexander Guschin; Magnus Unemo
Journal:  APMIS       Date:  2015-08-24       Impact factor: 3.205

3.  Management of gonococcal infection among adults and youth: New key recommendations.

Authors:  Lisa Pogany; Barbara Romanowski; Joan Robinson; Margaret Gale-Rowe; Cathy Latham-Carmanico; Christine Weir; Tom Wong
Journal:  Can Fam Physician       Date:  2015-10       Impact factor: 3.275

4.  Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone.

Authors:  Makoto Ohnishi; Daniel Golparian; Ken Shimuta; Takeshi Saika; Shinji Hoshina; Kazuhiro Iwasaku; Shu-ichi Nakayama; Jo Kitawaki; Magnus Unemo
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

Review 5.  Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea.

Authors:  Magnus Unemo; Robert A Nicholas
Journal:  Future Microbiol       Date:  2012-12       Impact factor: 3.165

6.  Rising trend of antimicrobial resistance among Neisseria gonorrhoeae isolates and the emergence of N. gonorrhoeae isolate with decreased susceptibility to ceftriaxone.

Authors:  T Bharara; P Bhalla; D Rawat; V K Garg; K Sardana; A Chakravarti
Journal:  Indian J Med Microbiol       Date:  2015 Jan-Mar       Impact factor: 0.985

7.  Performance of three nucleic acid amplification tests for detection of Chlamydia trachomatis and Neisseria gonorrhoeae by use of self-collected vaginal swabs obtained via an Internet-based screening program.

Authors:  Billie Jo Masek; Nick Arora; Nicole Quinn; Bulbul Aumakhan; Jeff Holden; Andrew Hardick; Patricia Agreda; Mathilda Barnes; Charlotte A Gaydos
Journal:  J Clin Microbiol       Date:  2009-04-22       Impact factor: 5.948

8.  Vaginal swabs are the optimal specimen for detection of genital Chlamydia trachomatis or Neisseria gonorrhoeae using the Cobas 4800 CT/NG test.

Authors:  Barbara Van Der Pol; Stephanie N Taylor; Oliver Liesenfeld; James A Williams; Edward W Hook
Journal:  Sex Transm Dis       Date:  2013-03       Impact factor: 2.830

9.  Fluoroquinolone-Resistant Mycoplasma genitalium, Southwestern France.

Authors:  Chloé Le Roy; Nadège Hénin; Sabine Pereyre; Cécile Bébéar
Journal:  Emerg Infect Dis       Date:  2016-09       Impact factor: 6.883

10.  Is the tide turning again for cephalosporin resistance in Neisseria gonorrhoeae in Europe? Results from the 2013 European surveillance.

Authors:  Michelle J Cole; Gianfranco Spiteri; Susanne Jacobsson; Rachel Pitt; Vlad Grigorjev; Magnus Unemo
Journal:  BMC Infect Dis       Date:  2015-08-11       Impact factor: 3.090

View more
  2 in total

Review 1.  [Nonviral sexually transmitted infections-epidemiology, clinical manifestations, diagnostic workup, therapy : Part 3: Treponemes, Gardnerella and trichomonads].

Authors:  P Nenoff; A Manos; I Ehrhard; C Krüger; U Paasch; P Helmbold; W Handrick
Journal:  Hautarzt       Date:  2017-02       Impact factor: 0.751

2.  Comparative Analysis of the Incidence of Selected Sexually Transmitted Bacterial Infections in Poland in 2010-2015: A Retrospective Cohort Study.

Authors:  Magda Orzechowska; Mateusz Cybulski; Elzbieta Krajewska-Kulak; Agnieszka Gniadek; Wiaczeslaw Niczyporuk
Journal:  J Clin Med       Date:  2022-02-14       Impact factor: 4.241

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.